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PLINICAL RESEARCH Coronary Artery Disease
eta-Analysis of Cardiovascular Outcomes Trials
omparing Intensive Versus Moderate Statin Therapy
hristopher P. Cannon, MD, Benjamin A. Steinberg, BA, Sabina A. Murphy, MPH,
essica L. Mega, MD, Eugene Braunwald, MD
oston, Massachusetts
OBJECTIVES The purpose of this study was to conduct a meta-analysis that compares the reduction of
cardiovascular outcomes with high-dose statin therapy versus standard dosing.
BACKGROUND Debate exists regarding the merit of more intensive lipid lowering with high-dose statin
therapy as compared with standard-dose therapy.
METHODS We searched PubMed and article references for randomized controlled trials of intensive
versus standard-dose statin therapy enrolling more than 1,000 patients with either stable
coronary heart disease or acute coronary syndromes. Four trials were identified: the TNT
(Treating to New Targets) and the IDEAL (Incremental Decrease in End Points Through
Aggressive Lipid-Lowering) trials involved patients with stable cardiovascular disease, and
the PROVE IT–TIMI-22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis in Myocardial Infarction-22) and A-to-Z (Aggrastat-to-Zocor) trials involved
patients with acute coronary syndromes. We carried out a meta-analysis of the relative odds
on the basis of a fixed-effects model using the Mantel-Haenszel method for the major
outcomes of death and cardiovascular events.
RESULTS A total of 27,548 patients were enrolled in the 4 large trials. The combined analysis yielded
a significant 16% odds reduction in coronary death or myocardial infarction (p  0.00001),
as well as a significant 16% odds reduction of coronary death or any cardiovascular event
(p  0.00001). No difference was observed in total or non-cardiovascular mortality, but a trend
toward decreased cardiovascular mortality (odds reduction 12%, p  0.054) was observed.
CONCLUSIONS Intensive lipid lowering with high-dose statin therapy provides a significant benefit over
standard-dose therapy for preventing predominantly non-fatal cardiovascular events. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.070Coll Cardiol 2006;48:438–45) © 2006 by the American College of Cardiology Foundation
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dumerous large, randomized, controlled trials have docu-
ented that cholesterol-lowering therapy with 3-hydroxy-
-methylglutaryl coenzyme A reductase inhibitors (statins)
educes the risk of death or cardiovascular events in popu-
ations with or without a history of coronary artery disease,
nd across a wide range of cholesterol levels (1).
Recent trials have demonstrated that high-dose statins
also referred to as intensive statin therapy) appear to be
ore effective than standard-dose statins at reducing cardio-
ascular events, as seen in the PROVE IT–TIMI-22 (Prava-
tatin or Atorvastatin Evaluation and Infection Therapy–
hrombolysis In Myocardial Infarction-22) and TNT
Treating to New Targets) trials (2,3). However, 2 trials, the
-to-Z (Aggrastat to Zocor) and IDEAL (Incremental
ecrease in End Points Through Aggressive Lipid Lower-
From the Thrombolysis In Myocardial Infarction Study Group, Cardiovascular
ivision, Department of Medicine, Brigham and Women’s Hospital and Harvard
edical School, Boston, Massachusetts. The PROVE IT–TIMI-22 trial was
ponsored by Bristol-Myers Squibb and Sankyo Co. LTD, and the A-to-Z trial was
ponsored by Merck. Dr. Cannon currently receives research grant support from
erck, AstraZeneca, and Schering-Plough, and serves on advisory boards and/or is a
onsultant to AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck,
chering-Plough, Pfizer, and Sanofi-Aventis. Mr. Steinberg is a research fellow
upported by The Stanley J. Sarnoff Endowment for Cardiovascular Science, Inc.,
reat Falls, Virginia. Dr. Braunwald receives research grant support from Bristol-
yers Squibb, Merck, Pfizer, and Schering-Plough.I
Manuscript received January 23, 2006; revised manuscript received March 30,
006, accepted April 4, 2006.ng) (4,5), had non-significant trends toward benefit of inten-
ive statin therapy for their pre-specified primary end point,
aising questions regarding the reliability of this observation. In
rder to determine more accurately the clinical utility of
ntensive statin therapy, we performed a meta-analysis of these
trials, which represent more than 100,000 patient-years of
bservation directly comparing high-dose versus standard-
ose statin therapy.
ETHODS
e performed a PubMed search for randomized clinical
rials comparing intensive statin therapy with standard-dose
tatin therapy, and carried out a hand search of references
rom these original articles and related reviews. Study
election criteria were randomized, controlled trials enroll-
ng more than 1,000 patients that reported clinical outcomes
s their primary end point. We intended to look at studies
hat were adequately powered to detect treatment effects on
linical events. Thus, similar to the Cholesterol Treatment
rialists’ (CTT) review of placebo-controlled trials (1), the
cope of our search was limited to those trials that random-
zed 1,000 patients or more and were sufficiently powered to
etect clinical end points.
Four randomized trials were identified. The PROVET–TIMI-22 (n  4,162) (2), A-to-Z (n  4,497) (4),
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August 1, 2006:438–45 Meta-Analysis of Intensive Statin TherapyNT (n  10,001) (3), and IDEAL (n  8,888) (5) trials
ielded a population of 27,548 patients with either stable
oronary heart disease or acute coronary syndromes (ACSs).
hese patients were randomized to standard-dose or high-
ose statin, as determined by the individual trial: pravastatin
0 mg versus atorvastatin 80 mg in the PROVE IT–
IMI-22 trial; 10 mg versus 80 mg atorvastatin in the TNT
rial; placebo followed by 20 mg simvastatin versus 40 mg
ollowed by 80 mg simvastatin in the A-to-Z trial; and
imvastatin 20 mg titrated to 40 mg versus 80 mg atorva-
tatin in the IDEAL trial. The following end points were
ompared across all of the trials: 1) the combined incidence
f coronary death or non-fatal myocardial infarction (MI);
) the combined incidence of coronary death or any cardio-
ascular event (MI, stroke, hospitalization for unstable
ngina, or revascularization); and 3) the incidence of stroke;
nd 4) the incidence of cardiovascular, non-cardiovascular,
nd all-cause mortality.
tatistical analysis. The absolute event rates through
ollow-up for mortality are presented for cardiovascular
eath and any cardiovascular events. Because different trials
Abbreviations and Acronyms
A-to-Z  Aggrastat-to-Zocor trial
ACS  acute coronary syndrome
CI  confidence interval
CTT  Cholesterol Treatment Trialists
IDEAL  Incremental Decrease in End
Points Through Aggressive
Lipid-Lowering trial
LDL  low-density lipoprotein
MI  myocardial infarction
NCEP  National Cholesterol Education
Program
OR  odds ratio
PROVE IT–TIMI-22  Pravastatin or Atorvastatin
Evaluation and Infection
Therapy–Thrombolysis In
Myocardial Infarction-22 trial
TNT  Treating to New Targets trial
able 1. Trial Design and Baseline Characteristics of the Four T
PROVE IT–TIMI-22 (2) A-to-Z
4,162 4,49
opulation Post-ACS Post-ACS
reatment arms 40 mg pravastatin vs. 80 mg
atorvastatin
Placebo (4 mont
mg simvastati
simvastatin (1
then 80 mg si
uration 24 months (mean) 721 days (media
un-in None None
rimary end point Death, MI, UA requiring
hospitalization,
revascularization (30 days),
stroke
CV death, MI,
for ACS, stro
to Z  Aggrastat to Zocor trial; ACS  acute coronary syndrome; CAD  cor
ncremental Decrease in End Points Through Aggressive Lipid-Lowering trial; MI  myo
nd Infection Therapy–Thrombolysis In Myocardial Infarction trial; TNT  Treating tosed varying definitions, subtle differences exist in the end
oint of coronary death or any adverse cardiovascular event.
he IDEAL and TNT trials both included cardiac arrest
ith resuscitation as a major event. Furthermore, the TNT
rial included only non-fatal, non–procedure-related MIs,
nd the definition of unstable angina varied (unstable angina
equiring hospitalization in the PROVE IT–TIMI-22 and
DEAL trials, readmission for ACS in the A-to-Z trial, and
ocumented angina in the TNT trial). In order to more
losely mirror the definitions used in the TNT and IDEAL
rials, the composite end point of all cardiovascular end
oints used for the PROVE IT–TIMI-22 and A-to-Z trials
iffers from that in the original manuscripts to include
evascularization at any time and only coronary death. In
ddition, low-density lipoprotein (LDL) values reported are
n-treatment means for the duration of the individual study
not medians, as reported for some trials), based on the
ntention-to-treat population. Thus, results presented here
ay appear to differ from those in the trials’ primary
ublications.
A meta-analysis was performed of the relative odds based
n a fixed-effects model using the Mantel-Haenszel
ethod. Heterogeneity between individual studies was in-
orporated into the summary estimate and was influenced
y trial sample size and the number of events observed. A
andom-effects model was also performed as a sensitivity
nalysis. Results are presented as odds ratios (ORs) with
heir 95% confidence intervals (CIs) and p values. A p value
f 0.05 was considered statistically significant.
ESULTS
tudy design and baseline characteristics for each of the 4
ualifying trials are shown in Table 1. The LDL cholesterol
evels in each arm of each trial are presented in Figure 1.
hese values are based on the intention-to-treat popula-
ions. The mean on-treatment LDL cholesterol concentra-
ions in the standard therapy arms ranged from 97 mg/dl
2.49 mmol/l) in the PROVE IT–TIMI-22 trial (2) to 104
Included in the Meta-Analysis
TNT (3) IDEAL (5)
10,001 8,888
Stable CAD Stable CAD
en 20
40 mg
th)
tatin
10 mg atorvastatin vs. 80 mg
atorvastatin
20 mg simvastatin vs. 80 mg
atorvastatin
4.9 yrs (median) 4.8 yrs (median)
10 mg atorvastatin (8 weeks)
per guidelines
None
ission CHD death,
Non–procedure-related
MI, resuscitation after
cardiac arrest, stroke
CHD death, MI, cardiac
arrest with resuscitation
artery disease; CHD  congenital heart disease; CV  cardiovascular; IDEAL rials
(4)
7
hs) th
n vs.
mon
mvas
n)
readm
ke
onary
cardial infarction; PROVE IT–TIMI-22  Pravastatin or Atorvastatin Evaluation
New Targets trial; UA  unstable angina.
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Meta-Analysis of Intensive Statin Therapy August 1, 2006:438–45g/dl (2.67 mmol/l) in IDEAL (5). The differences in
DL between treatment arms within a trial ranged from a
ow of 23 mg/dl (0.59 mmol/l) in the IDEAL trial (5) to a
igh of 32 mg/dl (0.82 mmol/l) in the PROVE IT–
IMI-22 and A-to-Z trials (2,4), in part based on differ-
nces in the percentage of patients on statin therapy at
aseline. The pooled analysis, in which approximately one-
ourth of the patients were on prior statin therapy, showed
hat with standard-dose therapy, LDL cholesterol declined
y 22% to a mean of 101 mg/dl (2.59 mmol/l), whereas with
igh-dose therapy, it declined by 42% to a mean of 75 mg/dl
igure 1. Low-density lipoprotein cholesterol (LDL-C) levels of trials com
eans, as not all individual LDL-C measurements were available.igure 2. Individual trials and pooled analysis showing a highly significant 16
.0001). CI  confidence interval; OR  odds ratio.1.92 mmol/l). This yielded a final difference in LDL of
5.7% (101 vs. 75 mg/dl) between the 2 treatment groups.
Individual and pooled analyses for coronary death or MI are
hown in Figure 2. Although each trial individually had lower
ates with intensive statin therapy when considered indepen-
ently, only the TNT trial had a significant difference. The
ooled analysis, however, yielded an overall significant odds
eduction of 16% for coronary death orMI (9.4% vs. 8.0%, OR
.84, 95% CI 0.77 to 0.91, p  0.00001).
The risk of coronary death or any adverse cardiovascular
vents (MI, stroke, hospitalization for unstable angina, or
high-dose to standard-dose statin therapy. *Values for trials are estimated% reduction in the risk of coronary death or myocardial infarction (p 
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August 1, 2006:438–45 Meta-Analysis of Intensive Statin Therapyny revascularization) was reduced significantly in the in-
ensive statin group in 3 of the 4 trials and neutral in the
-to-Z trial (Fig. 3). The pooled analysis yielded a signif-
cant 16% reduction of coronary death or any cardiovascular
vents (32.3% vs. 28.8%, OR 0.84, 95% CI 0.80 to 0.89,
 0.0000001).
Cardiovascular death tended to be lower in the high-dose
roups in 3 trials, and neutral in the IDEAL trial. Pooling
he data yielded a trend to reduction in cardiovascular
ortality by 12% (3.8% vs. 3.3%, OR 0.88, 95% CI 0.78 to
.00, p  0.054) (Fig. 4A). Rates for non-cardiovascular
eath and total mortality were also compared. Although 1
rial (TNT) reported a non-significant increase in non-
ardiovascular death in the intensive therapy group (3.2% vs.
.5%), 1 trial was neutral (A-to-Z) and 2 showed non-
ignificantly lower rates. The pooled rates revealed no
ignificant differences between the 2 groups (2.4% in the
tandard-dose group vs. 2.5% in the intensive, OR 1.03,
5% CI 0.88 to 1.20, p  0.73) (Fig. 4B). The effects on
ll-cause mortality demonstrated a trend toward benefit in
he PROVE IT–TIMI-22 and A-to-Z trials, but a neutral
ffect in TNT and IDEAL. In the cumulative experience,
here was a non-significant 6% reduction in all-cause
ortality (6.2% vs. 5.9%, OR 0.94, 95% CI 0.85 to 1.04,
 0.20) (Fig. 4C). Data for rates of stroke yielded a
ignificant odds reduction of 18% (2.8% vs. 2.3%, OR 0.82,
5% CI 0.71 to 0.96, p  0.012) when pooled across all 4
rials (Fig. 5). Each of the observations was similar when the
nalysis was performed with a random-effects model. For
he end point of coronary heart disease death or MI, the
andom-effects model yielded an odds reduction of 16.5%
OR 0.835, 95% CI 0.77 to 0.91, p  0.0001).
Severe adverse events, as reported by the trials in their
igure 3. Individual trials and pooled analysis showing a highly signific
myocardial infarction, stroke, hospitalization for unstable angina, or revasriginal manuscripts, are listed in Table 2 (6). tISCUSSION
his analysis, involving more than 100,000 patient-years of
bservation, found a highly significant 16% reduction of
oronary death or MI (p  0.00001) and, similarly, a 16%
eduction in coronary death or any cardiovascular events in
atients receiving high-dose statin therapy versus those
eceiving standard-dose therapy (p  1012). Although
here was also a favorable trend in reduction of cardiovas-
ular death with high-dose statins, the predominant benefit
as seen in preventing the non-fatal events of MI, stroke,
nstable angina, and revascularization. These data under-
core the significant clinical benefit of high-dose statin
herapy over standard doses in patients with known coro-
ary artery disease, whether treated immediately after an
cute coronary event or in the stable secondary prevention
etting.
Extrapolating these data indicates that for every million
atients with chronic or acute coronary artery disease, such
s those entered into these trials, treated for 5 years,
ntensive rather than standard statin dosing would prevent
ore than 35,000 cardiovascular events (including more
han 14,000 coronary deaths or MIs). On the basis of our
nalysis, this yields a number needed to treat of just 29
atients (for 2 years following an ACS, or for 5 years in
table patients) to prevent a cardiovascular event. It should
e recalled that these benefits are in addition to those
chieved by standard statin therapy, which has been shown
o be highly effective (1). Placebo-controlled standard-dose
tatin trials showed a reduction in cardiovascular mortality
y 20%, and of major cardiovascular events by 25% (1).
hus, when the present analysis is considered in light of the
eta-analysis of placebo-controlled trials, it is possible that
6% reduction in the risk of coronary death or any cardiovascular event
ization) (p  0.0001). CI  confidence interval; OR  odds ratio.he benefit of high-dose statins as compared with placebo
F
m
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Meta-Analysis of Intensive Statin Therapy August 1, 2006:438–45igure 4. Individual and pooled analyses showing non-significant trend in reduction of cardiovascular death (A), no increased risk of non-cardiovascular
ortality (B), and a non-significant trend toward decreased overall mortality with high-dose statins (C). CI  confidence interval; OR  odds ratio.
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August 1, 2006:438–45 Meta-Analysis of Intensive Statin Therapyould be a 40% reduction in cardiovascular events for the
arge number of patients at risk who are not currently on any
tatin.
Our data expand upon prior analyses of LDL reduction
ersus clinical event reductions. Although we did not have
omplete patient-level data to precisely gauge risk reduction
er unit LDL reduction, our study is consistent with the
reviously published rates from the CTT meta-analysis,
here roughly 1.8 mg/dl reduction in LDL led to a 1%
eduction in cardiovascular events (1). Thus, the 26 mg/dl
ifference in LDL we observed in this analysis would be
xpected to lead to approximately a 14% decrease in cardio-
ascular events, and we observed a 16% reduction in events.
owever, this analysis is a comparison of LDL lowering
sing different doses of statins to reduce cardiovascular
vents. Because we lack patient-level data and because
tatins have been shown to reduce other markers of cardio-
ascular disease (such as C-reactive protein) (7), we cannot
ake any conclusions as to the expected risk reduction
hrough other means of lowering LDL.
In determining current practice patterns of the use of
tatins, several surveys have shown underutilization of these
igure 5. Individual and pooled analyses demonstrating a significant 18
R  odds ratio.
able 2. Severe Adverse Event Rates for Each Trial
Trial
Rhabdomyolysis (n)*
Standard Dose High D
ROVE IT–TIMI-22 (2,6) (n  4,162) 0% 0
-to-Z (4) (n  4,497) 0% 0.13
NT (3) (n  10,001) 0.06% 0.04
DEAL (5) (n  8,888) 0.07% 0.05
ollow-up periods are 2 years for the PROVE IT–TIMI-22 and A-to-Z trials and 5 y
T–TIMI-22 trial were back-calculated from numbers presented in published manuscr
nd a definition of CK levels higher than 10,000 U/l for A to Z. †A to Z reported 1 add
T–TIMI-22 trial reported elevations in ALT; IDEAL reported as number of abnormalit
ALT  alanine aminotransferase; AST  aspartate aminotransferase; CK  creatine kgents (8–12). In some series, 40% to 50% of patients who
ave evidence of cardiovascular disease and are eligible for
tatin therapy by National Cholesterol Education Program
NCEP) III Guidelines do not receive any statin therapy.
his was highlighted by the guidelines committee as a
ajor national priority—to expand the use of statins to all
ligible patients (13). In addition, studies of “real-world”
linical practice have indicated significant under-dosing of
tatins in high-risk populations (8). In 1 recent report,
early half of the patients were receiving doses below those
ested in clinical trials (e.g., 10 mg of simvastatin or
ravastatin), which would be associated with smaller reduc-
ions in LDL and which have not been shown to reduce
linical events (8). Conversely, fewer than 5% were taking
igh-intensity statin therapy (80 mg simvastatin or 80 mg
torvastatin) (8–11). Although some studies have noted
mprovement in the prescription of high-dose statins in the
ast year in response to the PROVE IT–TIMI-22 trial
2,9), use remains quite low (5% to 15%) (12). With the
ubstantial benefits of high-dose compared with standard-
ose statin therapy seen in this meta-analysis, not only
hould physicians and health-care systems work to improve
uction of stroke with intensive statin therapy. CI  confidence interval;
CK >10  ULN (n)†
AST and/or ALT
>3  ULN (n)‡
Standard Dose High Dose Standard Dose High Dose
0.10% 0.15% 1.1% 3.3%
0.04% 0.4% 0.36% 0.84%
0% 0% 0.18% 1.2%
0% 0% 0.16% 1.37%
r the TNT and IDEAL trials. Percentages for all events except those in the PROVE
ases were based on the treating physician’s diagnosis for the TNT and IDEAL trials,
l patient with an alcohol-related rise in CK without muscle symptoms. ‡The PROVEose
%
%
%
%
ears fo
ipts. *C
itionaies.
inase; ULN  upper limit of normal; other abbreviations as in Table 1.
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Meta-Analysis of Intensive Statin Therapy August 1, 2006:438–45he percentage of patients on statins, they should ensure that
atients receive the appropriate, evidence-based dose.
This meta-analysis also underscores the role of high-dose
tatins in preventing stroke. Although much attention in
revention of stroke has focused on antithrombotic therapy,
ew advances in this approach have occurred in recent
tudies (14). The meta-analysis of all placebo-controlled
tatin trials showed a relative risk reduction of stroke by 17%
1). Our data indicate that high-dose statins, compared to
tandard-dose statins, such as were employed in the previ-
usly cited meta-analysis (1), could significantly enhance
hat effect by an additional 18%, to yield an overall reduction
f stroke by approximately one-third. This represents an
mportant intervention for patients, most of whom do not
ave a history of cerebrovascular disease.
Concerns have surfaced about the possibility of an asso-
iated increase in non-cardiovascular mortality with high
oses compared with standard doses of statins as a result of
trend toward increased non-cardiovascular mortality in the
NT trial (3,15). However, our pooled analyses, which
ncluded the TNT trial, found essentially identical rates in
he high-dose (2.5%) versus the standard-dose (2.4%)
roups (p  0.73). In addition, the recent CTT review of
0,056 patients in 14 placebo-controlled trials found not
nly no increase in non-vascular mortality, but a significant
2% reduction in all-cause deaths (p  0.0001) (1). Thus,
uch of the concern for both standard-dose and high-dose
tatin use and non-cardiovascular death seems to be merely
hance observation in an individual trial or anecdotal evi-
ence, but not supported by the totality of the evidence.
Therefore, results of this meta-analysis should have
ubstantial implications for both physicians and their pa-
ients. In an effort to provide for maximum reduction of
ardiovascular events, intensive statin therapy should be
onsidered in the same realm as other proven therapies such
s smoking cessation and aspirin use for secondary preven-
ion (16,17). Accordingly, we believe these data support the
CEP’s 2004 amendment to the Adult Treatment Panel
II Guidelines (13,18) and should provide the impetus for
he guidelines committee to consider upgrading the target
f 70 mg/dl from “optional” to “recommended” for high-
isk patients (such as those enrolled in these trials), thereby
aximizing the opportunity to achieve the benefits of
ntensive statin therapy demonstrated here.
tudy limitations. Although 27,548 patients is the largest
nalysis of intensive statin therapy to date, it remains under-
owered to detect a statistical difference in cardiovascular death
nd total mortality (19). An additional trial comparing 80 mg
f simvastatin to 20 mg of simvastatin, SEARCH (Study of
he Effectiveness of Additional Reductions in Cholesterol and
omocysteine) (20), is ongoing—and this trial combined with
ur meta-analysis should provide further information on these
important end points. The duration of treatment and
ollow-up differed between the trials, but was relatively long-
erm for each of the respective conditions (2 years for the ACS
rials, and 5 years for the trials of stable coronary artery disease).owever, similar differences in duration of trials are present in
ost other meta-analyses, including the overview of prior
tatin-versus-placebo trials where durations ranged from 3
ears (in several trials such as ASCOT [Anglo-Scandinavian
ardiac Outcomes Trial] [21], CARDS [Collaborative Ator-
astatin Diabetes Study] [22], and PROSPER [PROspective
tudy of Pravastatin in the Elderly at Risk] [23]) to 5 years (in
thers). We did not have individual patient data, and thus
ould not assess the degree of LDL lowering versus clinical
enefit as was done in the CTT analysis, but this latter
ollaborative group is in the process of collecting the data to
arry out such an analysis. We cannot determine from this
nalysis whether the benefit is seen because high-dose statins
ere used or because low LDL levels were achieved. Thus, we
re not able to say, if a patient achieved an LDL of70 mg/dl
sing moderate-dose statin, whether outcomes would be better
f a higher-dose statin were used (which would achieve an
DL of even lower). Ongoing trials are addressing whether
urther reductions can be seen with even higher-intensity LDL
owering. Finally, we did not assess cost-benefit in this analysis;
hese analyses are ongoing in individual trials and should be
seful to determine the cost (or potential savings) associated
ith the observed clinical benefit of this more intensive
econdary prevention strategy.
onclusions. Intensive lipid lowering with statins provides
significant benefit over standard-dose statin therapy for
reventing non-fatal cardiovascular events, including stroke,
ith a trend toward decreasing cardiovascular mortality as
ell. These data support a broader use of intensive statin
herapy for patients with stable coronary heart disease, as
ell as those with a recent ACS.
eprint requests and correspondence: Dr. Christopher P. Cannon,
IMI Study Group, Cardiovascular Division, Brigham andWomen’s
ospital, 75 Francis Street, Boston, Massachusetts 02115. E-mail:
pcannon@partners.org.
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